Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Pinetarsol 2.3% solution
1305020C0BSACFD
|
Pinetarsol | Tars | Skin | No data available |
|
Pinewood Bites and Stings Relief 1% cream
1304000V0CXAAAD
|
Pinewood (Hydrocortisone) | Hydrocortisone | Skin | No data available |
|
Pinewood Cold Sore 5% cream
1310030C0BPAAAA
|
Pinewood (Aciclovir) | Aciclovir | Skin | No data available |
|
Pinmactil 80mg modified-release tablets
0212000M0BDAAAD
|
Pinmactil | Fluvastatin sodium | Cardiovascular System | No data available |
|
Pioglitazone 15mg/5ml oral suspension
0601023B0AAAEAE
|
Pioglitazone hydrochloride | Pioglitazone hydrochloride | Endocrine System | No data available |
|
Pioglitazone 30mg/5ml oral suspension
0601023B0AAADAD
|
Pioglitazone hydrochloride | Pioglitazone hydrochloride | Endocrine System | No data available |
|
Pioglitazone 45mg/5ml oral suspension
0601023B0AAAFAF
|
Pioglitazone hydrochloride | Pioglitazone hydrochloride | Endocrine System | No data available |
|
Piperacillin 2g / Tazobactam 250mg inf vials
0501014S0AAAAAA
|
Piperacillin/tazobactam | Piperacillin sodium/tazobactam sodium | Infections | No data available |
|
Piperacillin 4g / Tazobactam 500mg inj vials
0501014S0AAACAC
|
Piperacillin/tazobactam | Piperacillin sodium/tazobactam sodium | Infections | No data available |
|
Piperaquine phosphate 320mg / Artenimol 40mg tablets
0504010ABAAAAAA
|
Piperaquine phosphate/artenimol | Piperaquine phosphate/artenimol | Infections | No data available |
|
Piperazine 4g / Senna 15.3mg oral powder sachets sugar free
0505010H0AAAEAE
|
Piperazine | Piperazine | Infections | No data available |
|
Pipobroman 25mg tablets
0801050BHAAAAAA
|
Pipobroman | Pipobroman | Malignant Disease and Immunosuppression | No data available |
|
Piportil Depot 100mg/2ml solution for injection ampoules
0402020V0BBABAB
|
Piportil Depot | Pipotiazine palmitate | Central Nervous System | No data available |
|
Piportil Depot 50mg/1ml solution for injection ampoules
0402020V0BBAAAA
|
Piportil Depot | Pipotiazine palmitate | Central Nervous System | No data available |
|
Pipotiazine 100mg/2ml solution for injection ampoules
0402020V0AAABAB
|
Pipotiazine palmitate | Pipotiazine palmitate | Central Nervous System | No data available |
|
Pipotiazine 50mg/1ml solution for injection ampoules
0402020V0AAAAAA
|
Pipotiazine palmitate | Pipotiazine palmitate | Central Nervous System | No data available |
|
Pirenzepine 100mg tablets
0103020P0AAACAC
|
Pirenzepine | Pirenzepine | Gastro-Intestinal System | No data available |
|
Pirenzepine 25mg tablets
0103020P0AAABAB
|
Pirenzepine | Pirenzepine | Gastro-Intestinal System | No data available |
|
Piroxicam 10mg dispersible tablets
1001010R0AAADAD
|
Piroxicam (Systemic) | Piroxicam | Musculoskeletal and Joint Diseases | No data available |
|
Piroxicam 20mg dispersible tablets
1001010R0AAAEAE
|
Piroxicam (Systemic) | Piroxicam | Musculoskeletal and Joint Diseases | No data available |
|
Piroxicam 20mg suppositories
1001010R0AAACAC
|
Piroxicam (Systemic) | Piroxicam | Musculoskeletal and Joint Diseases | No data available |
|
Piroxicam 20mg/1ml solution for injection ampoules
1001010R0AAAHAH
|
Piroxicam (Systemic) | Piroxicam | Musculoskeletal and Joint Diseases | No data available |
|
Piroxicam betadex 20mg tablets
1001010R0AAAKAK
|
Piroxicam (Systemic) | Piroxicam | Musculoskeletal and Joint Diseases | No data available |
|
Pirozip 10 capsules
1001010R0BDAAAA
|
Pirozip | Piroxicam | Musculoskeletal and Joint Diseases | No data available |
|
Pirozip 20 capsules
1001010R0BDABAB
|
Pirozip | Piroxicam | Musculoskeletal and Joint Diseases | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.